

North Yorkshire & York Area Prescribing Committee

Summary of decisions made regarding new product requests considered at a meeting of the Committee on the 4th May 2022

Classification of products:

- G** **Green drug** - Can be initiated and prescribed in all care settings **○**- Second line / alternative green drug
- ASR** **Amber Specialist Recommendation drug** - Can be recommended by a specialist for initiation in primary care
- ASI** **Amber Specialist Initiation drug** – Initiated by a specialist and transferred to primary care once the patient stabilised. In some cases there may be a further restriction for use outlined - these will be defined in each case.
- ASC** **Amber Shared Care drug** - These are specialist drugs which must be initiated by the specialist, but with the potential to transfer to primary care within written and agreed shared care protocols and according to the agreed process for transfer of care
- R** **Red drug** - Drugs that should remain under the total responsibility of the specialist. Usually considered as “hospital only” drugs
- BLACK** **Not Approved** - Drugs that have been considered by the APC or other approved body and are not approved for prescribing within North Yorkshire & York.
- GREY** **Not Reviewed** - Drugs that haven't been reviewed by the APC yet. This usually means that no application has been received or that an application is in progress. These drugs are not normally considered appropriate for prescribing in North Yorkshire & York.



Product	Decision			Comments/notes
	Approved	Refused	Deferred	
1) Requests deferred from previous meetings				
Oestriol 0.03mg pessary (Imvaggis®):	✓ G			A more cost-effective alternative to Vagifem® for local treatment of vaginal symptoms of estrogen deficiency in postmenopausal women. Confirmed all stakeholders are happy to add to formulary.
2) New Requests				
Lyumjev® Insulin			✓	Decision deferred to get more information about place in therapy compared to Fiasp® and Humalog® biosimilars.
3) New formulations & extensions to use				
Nil this month				
5) Products considered by NICE				
TA774: Lenalidomide for relapsed or refractory mantle cell lymphoma (terminated appraisal)	✓ BLACK for this indication			The formulary will reflect the TAG – NHS England is the responsible commissioner.

DECISION SUMMARY

Product	Decision			Comments/notes
	Approved	Refused	Deferred	
TA776: Pitolisant hydrochloride for treating excessive daytime sleepiness caused by obstructive sleep apnoea	✓ BLACK for this indication			The formulary will reflect the TAG – CCGs are the responsible commissioner.
TA777: Solriamfetol for treating excessive daytime sleepiness caused by obstructive sleep apnoea	✓ BLACK for this indication			The formulary will reflect the TAG – CCGs are the responsible commissioner.
TA778: Pegcetacoplan for treating paroxysmal nocturnal haemoglobinuria	✓ R			The formulary will reflect the TAG – NHS England is the responsible commissioner.
TA779: Dostarlimab for previously treated advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency	✓ R			The formulary will reflect the TAG – NHS England is the responsible commissioner.
TA780: Nivolumab with ipilimumab for untreated advanced renal cell carcinoma	✓ R			The formulary will reflect the TAG – NHS England is the responsible commissioner.
TA781: Sotorasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer	✓ R			The formulary will reflect the TAG – NHS England is the responsible commissioner.
TA782: Tagraxofusp for treating blastic plasmacytoid dendritic cell neoplasm (terminated appraisal)	✓ BLACK for this indication			The formulary will reflect the TAG – NHS England is the responsible commissioner.
HST18: Atidarsagene autotemcel for treating metachromatic leukodystrophy	✓ R			The formulary will reflect the TAG – NHS England is the responsible commissioner.
6) Appeals against earlier decisions by the APC				
None				

DECISION SUMMARY

Product	Decision			Comments/notes
	Approved	Refused	Deferred	
7) Miscellaneous formulary decisions by the APC				
Nil this month.				

The following guidelines were presented to and approved at the May 2022 meeting of the APC:

- TEWV Bipolar disorder under 18s prescribing tips
- TEWV Dementia Care Pathway AChEI decision aid (updated)
-

The following shared care guidelines were presented to and received for information at the May 2022 meeting of the APC:

- Nil this month.

Other documents presented to and approved at the May 2022 meeting of the APC:

- NY&Y APC Dosulepin Position Statement
- Clinically Assisted Hydration In Palliative Care Policy V5